Clinical Trials
28 trialsKirros
Genentech, Inc.
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
Northwestern University
Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion
Samsung Medical Center
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Replimune, Inc.
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Coherus Oncology, Inc.
TERTIO
Centre Hospitalier Universitaire de Besancon
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
University Health Network, Toronto
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
M.D. Anderson Cancer Center
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
ATTACH
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
(HCC)
Inova Health Care Services
STRATUM
National Cancer Centre, Singapore
AB-LATE02
University Hospital, Montpellier
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
Sun Yat-sen University
LOST-B
University of Texas Southwestern Medical Center
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Academic and Community Cancer Research United
FLORA
University Hospital Heidelberg
PhotonAB
Chang Gung Memorial Hospital
FMT in IT-refractory HCC - FAB-HCC Pilot Study
Medical University of Vienna
ABE-LIVER
University Hospital, Grenoble
ALERT-HCC
Asan Medical Center
Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
Yale University
Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Hoosier Cancer Research Network
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
Sun Yat-sen University
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
OHSU Knight Cancer Institute
Efficacy and Safety of T+A+RAD in HCC
Fudan University